Digirad (DRAD) Downgraded by ValuEngine to “Hold”

ValuEngine lowered shares of Digirad (NASDAQ:DRAD) from a buy rating to a hold rating in a report released on Sunday morning.

Several other brokerages have also recently issued reports on DRAD. B. Riley reaffirmed a buy rating and set a $6.00 target price on shares of Digirad in a research report on Thursday, October 5th. TheStreet cut Digirad from a c rating to a d+ rating in a research report on Friday, November 3rd.

Shares of Digirad (NASDAQ:DRAD) opened at $2.60 on Friday. The company has a quick ratio of 1.07, a current ratio of 1.44 and a debt-to-equity ratio of 0.36. Digirad has a one year low of $1.90 and a one year high of $5.68. The company has a market capitalization of $52.14, a P/E ratio of -4.48 and a beta of 1.89.

Digirad (NASDAQ:DRAD) last announced its quarterly earnings data on Friday, November 3rd. The medical equipment provider reported $0.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.04. Digirad had a positive return on equity of 9.82% and a negative net margin of 9.93%. The firm had revenue of $28.56 million during the quarter, compared to analysts’ expectations of $31.21 million. equities research analysts expect that Digirad will post 0.09 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the stock. Macquarie Group Ltd. purchased a new position in shares of Digirad during the third quarter valued at approximately $367,000. New York State Common Retirement Fund boosted its position in shares of Digirad by 22.0% during the third quarter. New York State Common Retirement Fund now owns 172,901 shares of the medical equipment provider’s stock valued at $597,000 after buying an additional 31,200 shares during the last quarter. Punch & Associates Investment Management Inc. boosted its position in shares of Digirad by 2.3% during the second quarter. Punch & Associates Investment Management Inc. now owns 1,277,781 shares of the medical equipment provider’s stock valued at $5,175,000 after buying an additional 28,159 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Digirad by 24.2% during the second quarter. Goldman Sachs Group Inc. now owns 42,810 shares of the medical equipment provider’s stock valued at $173,000 after buying an additional 8,347 shares during the last quarter. Finally, Connors Investor Services Inc. purchased a new position in shares of Digirad during the second quarter valued at approximately $185,000. 53.08% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.chaffeybreeze.com/2018/01/04/digirad-drad-downgraded-by-valuengine-to-hold.html.

About Digirad

Digirad Corporation provides healthcare solutions. The Company’s segments include Diagnostic Services, Mobile Healthcare, Diagnostic Imaging and Medical Device Sales and Services. Through Diagnostic Services, the Company offers an imaging services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply